Tumor‐associated antigen TA‐90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma

TA‐90 is a tumor‐associated antigen first identified in the urine and sera of patients with metastatic melanoma. In the early stages of disease, TA‐90 is present in circulating immune complexes (ICs) that may be detected with an antigen specific enzyme‐linked immunosorbent assay (ELISA). In this study, the authors evaluated the efficacy of the TA‐90 IC assay in detecting subclinical metastasis of early stage melanoma and predicting the survival of patients with this disease.

[1]  J. Hansson Systemic therapy of malignant melanoma , 1997, Medical oncology.

[2]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Morton,et al.  Vaccine therapy for malignant melanoma , 1996, CA: a cancer journal for clinicians.

[4]  C. Balch,et al.  Finally, a successful adjuvant therapy for high-risk melanoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Schadendorf,et al.  Serum manganese superoxide dismutase is a new tumour marker for malignant melanoma , 1995, Melanoma research.

[6]  K. Wakamatsu,et al.  Evaluation of melanin‐related metabolites as markers of melanoma progression , 1994, Cancer.

[7]  D L Morton,et al.  Multivariate analysis of the relationship between survival and the microstage of primary melanoma by clark level and breslow thickness , 1993, Cancer.

[8]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[9]  D. Morton,et al.  Monoclonal antibody‐based ELISA to detect glycoprotein tumor‐associated‐antigen‐specific immune complexes in cancer patients , 1992, Journal of clinical laboratory analysis.

[10]  R. Gupta,et al.  Characterization of a 90‐100 kDa tumor‐associated antigen in the sera of melanoma patients , 1990, International journal of cancer.

[11]  A. Cochran,et al.  Occult Tumor Cells in the Lymph Nodes of Patients with Pathological Stage I Malignant Melanoma An Immunohistological Study , 1988, The American journal of surgical pathology.

[12]  R. Gupta Circulating immune complexes in malignant melanoma. , 1988, Disease markers.

[13]  J. Morote Robles [What...about tumor markers]. , 1988, Actas urologicas espanolas.

[14]  C. Balch,et al.  A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.

[15]  M. Mihm,et al.  Prognostic Factors for Patients with Clinical Stage I Melanoma of Intermediate Thickness (1.51–3.99 mm)* A Conceptual Model for Tumor Growth and Metastasis , 1982 .

[16]  R. Gupta,et al.  Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms. , 1980, The Journal of surgical research.